drugset / Trial / NCT02625714

Safety/Tolerability and Pharmacokinetic Study of SID142

NCT02625714

Phase 1 Completed 41 enrolled SK Chemicals Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

A randomized, open-label, oral multiple dosing, two-part, two-way crossover clinical trial to evaluate the safety/tolerability and pharmacokinetic profiles of SID142 in healthy volunteers

Timeline

Start
2015-06
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cilostazol Small molecule 100 mg Oral
Subject Cilostazol Small molecule 200 mg Oral
Subject ginko biloba leaf extract Unknown 80 mg Oral
Subject ginko biloba leaf extract Unknown 160 mg Oral

Indications